Natera, Inc.
NTRA
株式のランク
#412
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
株価
$406.01
時価総額
$58.52B
変化（1日）
1.65%
変化（1年）
115.28%
国
US
取引 Natera, Inc. (NTRA)
カテゴリー
Healthcare
Natera, Inc.（NTRA）のP/E比率
October 2026 時点のP/E比率 TTM -290.26
Natera, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -290.26 です。2023 年末時点での P/E は -16.57 でした。
Natera, Inc. の P/E 比率の履歴（2012 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -290.26 | 179.96% |
| 2024 | -103.68 | 525.80% |
| 2023 | -16.57 | 129.58% |
| 2022 | -7.22 | -59.75% |
| 2021 | -17.93 | -48.91% |
| 2020 | -35.09 | 86.94% |
| 2019 | -18.77 | 198.53% |
| 2018 | -6.29 | 78.85% |
| 2017 | -3.52 | -44.11% |
| 2016 | -6.29 | -14.08% |
| 2015 | -7.32 | -94.29% |
| 2014 | -128.17 | 620.30% |
| 2013 | -17.79 | 2,308.87% |
| 2012 | -0.74 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 36.15 | -112.46% |
US
|
|
| 39.77 | -113.70% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -111.78% |
US
|
|
| 32.24 | -111.11% |
US
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。